Abstract
Many men with prostate cancer will develop hormonal resistance. There are now multiple treatment options that have been shown to modestly improve overall survival in the metastatic castrate-resistant prostate cancer (mCRPC) setting. There are numerous other exciting agents that will likely reach the market in the next few years.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 64-69 |
| Number of pages | 6 |
| Journal | Journal of Managed Care Medicine |
| Volume | 17 |
| Issue number | 1 |
| State | Published - 2014 |
ASJC Scopus subject areas
- Health Policy
